Oncotarget: Progression in high-risk non-muscle invasive bladder cancer

Oncotarget


published ”


A higher De Ritis ratio (AST/ALT) is a risk factor for progression in high-risk non-muscle invasive bladder cancer


” which reported that a recent study revealed that a high De Ritis ratio was a risk factor in some solid malignancies.

This

Oncotarget

study examined the importance of the De Ritis ratio as a prognostic marker in high-risk NMIBC.

This


Oncotarget


study examined the importance of the De Ritis ratio as a prognostic marker in high-risk NMIBC

Among these patients, 32 patients developed recurrent disease and 15 patients showed progression.

A multivariate analysis revealed that non-BCG treatment was an independent risk factor for recurrence, and a higher De Ritis ratio was an independent risk factor for cancer progression.

The De Ritis ratio might be a risk factor for progression in high-risk NMIBC.

The De Ritis ratio might be a risk factor for progression in high-risk NMIBC

Dr. Takashi Kawahara from

The Yokohama City University Medical Center

said, ”

Bladder cancer is the eleventh most common malignant disease in the world, and non-muscle invasive bladder cancer (NMIBC) accounts for 75% of all bladder cancer cases.

”

The serum aspartate aminotransaminase /alanine aminotransaminase ratio was first reported by De Ritis in 1957, since then this ratio has been called

the De Ritis ratio

.

A high De Ritis ratio was reported to be a poor prognostic marker in some solid malignancies.

In genitourinary cancer, a high De Ritis ratio was reported to be a poor prognostic marker in prostate, renal, and urothelial carcinoma.

In other solid malignancies including breast and lung cancer, a high De Ritis ratio was also reported to be a poor prognostic marker.

This study examined the importance of the De Ritis ratio as a prognostic marker in high-risk NMIBC.

The Kawahara Research Team concluded in their

Oncotarget Research Output

that first, the study was retrospective in nature.

To reveal the usefulness of the De Ritis ratio as a biomarker, a longer-term study of a larger population with a prospective design should be performed.

Third, this study showed higher age in the higher De Ritis group.

No previous study showed the correlation between AST/ALT value and age.

Thus, further study is needed.

###

DOI

–

https:/

/

doi.

org/

10.

18632/

oncotarget.

27944

Full text

–

https:/

/

www.

oncotarget.

com/

article/

27944/

text/

Correspondence to

– Takashi Kawahara –

[email protected]

Keywords

–


AST

,

ALT

,

De Ritis

,

high risk NMIBC

About Oncotarget

Oncotarget

is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit

https:/

/

www.

oncotarget.

com

or connect with:

SoundCloud –


https:/

/

soundcloud.

com/

oncotarget



Facebook –


https:/

/

www.

facebook.

com/

Oncotarget/

Twitter –


https:/

/

twitter.

com/

oncotarget



LinkedIn –


https:/

/

www.

linkedin.

com/

company/

oncotarget



Pinterest –


https:/

/

www.

pinterest.

com/

oncotarget/

Reddit –


https:/

/

www.

reddit.

com/

user/

Oncotarget/

Oncotarget

is published by Impact Journals, LLC please visit

https:/

/

www.

ImpactJournals.

com

or connect with

@ImpactJrnls

Media Contact



[email protected]



18009220957×105

Copyright © 2021 Impact Journals, LLC

Impact Journals is a registered trademark of Impact Journals, LLC